Tara Hiltke

Chemistry · Physical Sciences

32h-index11.4kcitations90works15.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Proteomics Techniques and Applications(49), Ubiquitin and proteasome pathways(23), Cancer, Lipids, and Metabolism(22), Mass Spectrometry Techniques and Applications(14), Cancer Genomics and Diagnostics(14)

Publications87 total

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Cell·2025· 33 citedOpen Access
Abstract 1852: NCI’s Clinical Proteomic Tumor Analysis Consortium: A proteogenomic cancer analysis program
Cancer Research·2024· 2 cited
Lessons learned: establishing a CLIA-equivalent laboratory for targeted mass spectrometry assays – navigating the transition from research to clinical practice
Clinical Proteomics·2024· 11 citedOpen Access
Lessons Learned: Establishing a CLIA-Equivalent Laboratory for Targeted Mass Spectrometry Assays – Navigating the Transition from Research to Clinical Practice
Research Square (Research Square)·2023· 1 citedOpen Access
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin
Cancer Cell·2023· 90 citedOpen Access
Deep learning integrates histopathology and proteogenomics at a pan-cancer level
Cell Reports Medicine·2023· 30 citedOpen Access
Proteogenomic insights suggest druggable pathways in endometrial carcinoma
Cancer Cell·2023· 44 citedOpen Access
Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation
Cell·2023· 156 citedOpen Access
Pan-cancer proteogenomics connects oncogenic drivers to functional states
Cell·2023· 92 citedOpen Access
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Data from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Abstract 2019: NCI’s clinical proteomic tumor analysis consortium analysis tools and resources
Cancer Research·2023
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Data from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Henry Rodriguez(45), Mehdi Mesri(33), Emily S. Boja(27), Amanda G. Paulovich(24), Christopher R. Kinsinger(23), Steven A. Carr(22), David Fenyö(21), D.R. Mani(21), Ana I. Robles(19), Bing Zhang(17), Karin Rodland(17), Li Ding(17), Alexey I. Nesvizhskii(16), Jeffrey R. Whiteaker(15), Antonio Colaprico(15), Matthew J. Ellis(14), Mathangi Thiagarajan(14), Chet Birger(14), Hui Zhang(13), Samuel Payne(13)